H.C. Wainwright analyst Sean Lee CFA reiterated a Buy rating on Gritstone Oncology (NASDAQ:GRTS) Inc on Wednesday, setting a price target of $24, which is approximately 7.77% above the present share price of $22.27.
Lee CFA expects Gritstone Oncology Inc to post earnings per share (EPS) of -$0.69 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Gritstone Oncology, with an average price target of $15.
The analysts price targets range from a high of $24 to a low of $4.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $939 thousand and a net profit of -$26.14 million. The company's market cap is $1.05 billion.
According to TipRanks.com, H.C. Wainwright analyst Sean Lee CFA is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 110.7% and a 75.76% success rate.
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham (NYSE:GHM) Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.